Drug combo heralds major shift in chronic lymphocytic leukemia treatment

A combination of two drugs keeps patients with chronic lymphocytic leukemia disease-free and alive longer than the current standard of care, according to a phase-3 clinical trial of more than 500 participants. The results of the trial are likely to change how most people with the common blood cancer are treated in the future.